Dr. Kathryn Lemberg is an Instructor of Oncology at the Sidney Kimmel Comprehensive Cancer Center. Her research, conducted with Johns Hopkins Drug Discovery, focuses on tumor metabolism and the development of new metabolic inhibitors to treat cancer. She has investigated novel glutamine antagonists in preclinical models of RAS-driven solid tumors. She is also interested in the effects of tumor metabolism on patient growth and development. Dr. Lemberg completed pediatrics residency training at Johns Hopkins and pediatric hematology-oncology fellowship training in the joint Johns Hopkins/National Cancer Institute program. She received her M.D. and Ph.D. degrees from the Medical Scientist Training Program at Columbia University in New York, where her graduate research focused on ferroptosis, a novel oxidative cell death in cancer models.

Dr. Lemberg sees pediatric and young adult sarcoma patients as part of the sarcoma team and has additional clinical focus on neurofibromatosis type I related solid tumors. more


  • Assistant Professor of Oncology

Departments / Divisions



  • MD; Columbia University College of Physicians and Surgeons (2012)


  • Pediatrics; Johns Hopkins University School of Medicine (2015)


  • Pediatric Hematology-Oncology; Johns Hopkins University School of Medicine (2020)
  • Pediatric Oncology; National Institutes of Health (2019)

Board Certifications

  • American Board of Pediatrics (Hematology-Oncology) (2021)
  • American Board of Pediatrics (Pediatrics) (2016)

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

Is this you? Edit Profile
back to top button